Daiichi Sankyo Gets Brazil, South Korea Rights to Esperion’s Hypercholesterolemia Drug

Daiichi Sankyo said on April 27 that it has obtained the exclusive rights to develop and commercialize Esperion Therapeutics’ hypercholesterolemia treatment bempedoic acid in Brazil, South Korea, and certain other regions in Asia. Under the pact, the Japanese drug major...read more